​
​

Aclaris Therapeutics (ACRS) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

ACRS Stock Forecast

Aclaris Therapeutics stock forecast is as follows: an average price target of $14.00 (represents a 345.86% upside from ACRS’s last price of $3.14) and a rating consensus of 'Buy', based on 5 wall street analysts offering a 1-year stock forecast.

ACRS Price Target

The average price target for Aclaris Therapeutics (ACRS) is $14.00 based on 1-year price targets from 5 Wall Street analysts in the past 3 months, with a price target range of $25.00 to $3.00. This represents a potential 345.86% upside from ACRS's last price of $3.14.

ACRS Analyst Ratings

Buy

According to 5 Wall Street analysts, Aclaris Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for ACRS stock is 0 'Strong Buy' (0.00%), 2 'Buy' (40.00%), 2 'Hold' (40.00%), 1 'Sell' (20.00%), and 0 'Strong Sell' (0.00%).

Aclaris Therapeutics Price Target by Analyst

DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Nov 06, 2024Alex ThompsonStifel Nicolaus$3.00$2.2731.87%-4.46%
Dec 01, 2022-Goldman Sachs$25.00$15.2264.26%696.18%
Row per page
Go to

The latest Aclaris Therapeutics stock forecast, released on Nov 06, 2024 by Alex Thompson from Stifel Nicolaus, set a price target of $3.00, which represents a 31.87% increase from the stock price at the time of the forecast ($2.27), and a -4.46% decrease from ACRS last price ($3.14).

Aclaris Therapeutics Price Target by Period

1M3M12M
# Anlaysts111
Avg Price Target$3.00$3.00$3.00
Last Closing Price$3.14$3.14$3.14
Upside/Downside-4.46%-4.46%-4.46%

In the current month, the average price target of Aclaris Therapeutics stock is $3.00, according to 1 Wall Street analyst offering twelve months forecast. The average price target represents a -4.46% decrease as opposed to Aclaris Therapeutics's last price of $3.14. This month's average price target is down 0.00% compared to last quarter, and down 0.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

DateCompanyPrevious RatingNew RatingRating Change
Sep 18, 2024H.C. WainwrightNeutralNeutralHold
Sep 18, 2024BTIGNeutralNeutralHold
Jan 11, 2024Stifel NicolausBuyBuyHold
Dec 18, 2023H.C. WainwrightUnderperformUnderperformHold
Dec 18, 2023Stifel NicolausBuyBuyHold
Mar 07, 2023BTIGBuyBuyHold
Dec 01, 2022Goldman Sachs-BuyInitialise
Apr 26, 2022Zacks Investment ResearchHoldSellDowngrade
Apr 25, 2022Zacks Investment Research-HoldDowngrade
Row per page
Go to

Aclaris Therapeutics's last stock rating was published by H.C. Wainwright on Sep 18, 2024. The company gave ACRS a "Neutral" rating, the same as its previous rate.

Aclaris Therapeutics Financial Forecast

Aclaris Therapeutics Revenue Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19Mar 19Mar 18
Revenue--------$17.57M$9.28M$1.87M$2.53M$7.75M$19.02M$1.53M$1.45M$1.50M$1.66M$1.82M$1.78M$1.58M$1.45M$2.05M$1.41M$1.09M$983.00K$5.87M$5.04M$1.12M
Avg Forecast$3.70M$3.50M$3.34M$3.24M$5.85M$1.57M$1.82M$1.93M$4.66M$1.57M$1.90M$1.75M$1.99M$1.60M$1.61M$1.60M$1.79M$1.77M$1.75M$1.48M$1.39M$1.47M$1.23M$1.13M$9.80M$5.92M$5.55M$4.81M$1.14M
High Forecast$12.74M$12.05M$11.51M$5.35M$11.69M$5.42M$6.26M$1.93M$11.32M$1.57M$6.54M$6.02M$6.87M$1.60M$1.61M$1.60M$1.79M$1.77M$1.75M$1.48M$1.39M$1.47M$1.23M$1.13M$9.80M$5.92M$5.55M$4.81M$1.37M
Low Forecast$738.33K$698.42K$666.99K$1.12M$1.73M$314.29K$362.58K$1.93M$834.83K$1.57M$379.03K$348.88K$397.90K$1.60M$1.61M$1.60M$1.79M$1.77M$1.75M$1.48M$1.39M$1.47M$1.23M$1.13M$9.80M$5.92M$5.55M$4.81M$912.65K
# Analysts11136334756322223456464474379
Surprise %--------3.77%5.90%0.98%1.45%3.89%11.88%0.95%0.91%0.84%0.94%1.04%1.20%1.14%0.99%1.67%1.25%0.11%0.17%1.06%1.05%0.98%

Aclaris Therapeutics's average Quarter revenue forecast for Mar 24 based on 4 analysts is $1.93M, with a low forecast of $1.93M, and a high forecast of $1.93M. ACRS's average Quarter revenue forecast represents a -89.02% decrease compared to the company's last Quarter revenue of $17.57M (Dec 23).

Aclaris Therapeutics EBITDA Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19Mar 19Mar 18
# Analysts11136334756322223456464474379
EBITDA--------$-4.05M$-31.58M$-31.82M$-31.32M$-14.88M$-16.28M$-27.59M$-21.10M$-22.61M$-20.95M$-17.91M$-28.47M$-13.80M$-10.07M$-10.99M$-15.01M$-18.27M$-53.69M$-47.65M$-35.34M$-30.01M
Avg Forecast$-3.70M$-3.50M$-3.34M$-3.24M$-5.85M$-1.57M$-1.82M$-27.54M$-4.66M$-1.57M$-1.90M$-25.04M$-24.18M$-1.60M$-1.61M$-22.76M$-1.79M$-1.77M$-1.75M$-27.65M$-1.39M$-1.47M$-1.23M$-12.66M$-9.80M$-5.92M$-5.55M$-30.48M$-30.61M
High Forecast$-738.33K$-698.42K$-666.99K$-1.12M$-1.73M$-314.29K$-362.58K$-22.03M$-834.83K$-1.57M$-379.03K$-20.03M$-19.34M$-1.60M$-1.61M$-18.21M$-1.79M$-1.77M$-1.75M$-22.12M$-1.39M$-1.47M$-1.23M$-10.13M$-9.80M$-5.92M$-5.55M$-24.38M$-24.49M
Low Forecast$-12.74M$-12.05M$-11.51M$-5.35M$-11.69M$-5.42M$-6.26M$-33.05M$-11.32M$-1.57M$-6.54M$-30.05M$-29.01M$-1.60M$-1.61M$-27.31M$-1.79M$-1.77M$-1.75M$-33.18M$-1.39M$-1.47M$-1.23M$-15.20M$-9.80M$-5.92M$-5.55M$-36.58M$-36.73M
Surprise %--------0.87%20.07%16.75%1.25%0.62%10.17%17.12%0.93%12.62%11.83%10.26%1.03%9.93%6.85%8.95%1.19%1.86%9.06%8.59%1.16%0.98%

undefined analysts predict ACRS's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Aclaris Therapeutics's previous annual EBITDA (undefined) of $NaN.

Aclaris Therapeutics Net Income Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19Mar 19Mar 18
# Analysts11136334756322223456464474379
Net Income--------$-1.49M$-29.26M$-29.57M$-26.40M$-33.29M$-21.23M$-16.67M$-17.47M$-22.80M$-21.15M$-18.16M$-28.75M$-13.17M$-10.66M$-11.60M$-15.59M$-18.59M$-55.32M$-49.88M$-37.56M$-30.23M
Avg Forecast$-10.94M$-10.47M$-9.28M$-9.10M$-9.79M$-407.88K$-14.61M$-27.85M$-24.59M$-34.25M$-32.13M$-25.32M$-24.39M$-27.89M$-25.55M$-23.02M$-26.02M$-20.08M$-19.61M$-27.93M$-21.92M$-22.28M$-25.31M$-13.15M$-2.50M$-49.19M$-54.00M$-32.40M$-30.83M
High Forecast$444.24K$424.94K$376.64K$-5.69M$-8.39M$16.55K$593.07K$-22.28M$-11.96M$1.39M$1.30M$-20.25M$-19.51M$-27.89M$-25.55M$-18.41M$-26.02M$-20.08M$-19.61M$-22.34M$-21.92M$-22.28M$-25.31M$-10.52M$-2.50M$-49.19M$-54.00M$-25.92M$-24.67M
Low Forecast$-45.72M$-43.73M$-38.76M$-11.95M$-11.89M$-1.70M$-61.03M$-33.42M$-28.57M$-143.06M$-134.20M$-30.38M$-29.27M$-27.89M$-25.55M$-27.62M$-26.02M$-20.08M$-19.61M$-33.52M$-21.92M$-22.28M$-25.31M$-15.78M$-2.50M$-49.19M$-54.00M$-38.88M$-37.00M
Surprise %--------0.06%0.85%0.92%1.04%1.37%0.76%0.65%0.76%0.88%1.05%0.93%1.03%0.60%0.48%0.46%1.19%7.45%1.12%0.92%1.16%0.98%

Aclaris Therapeutics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. ACRS's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

Aclaris Therapeutics SG&A Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19Mar 19Mar 18
# Analysts11136334756322223456464474379
SG&A--------$3.30M$7.09M$8.32M$8.79M$7.15M$5.81M$6.08M$6.10M$6.94M$5.98M$5.87M$4.83M$4.90M$3.86M$5.57M$6.20M$6.61M$6.29M$15.17M$18.02M$17.49M
Avg Forecast$11.16M$10.56M$10.08M$9.78M$17.64M$4.75M$5.48M$5.82M$14.05M$4.75M$5.73M$5.27M$6.02M$4.83M$4.86M$4.82M$5.40M$5.34M$5.27M$4.47M$4.19M$4.43M$3.71M$3.39M$29.57M$17.87M$16.73M$14.52M$3.44M
High Forecast$38.44M$36.36M$34.73M$16.13M$35.27M$16.36M$18.88M$5.82M$34.16M$4.75M$19.73M$18.16M$20.72M$4.83M$4.86M$4.82M$5.40M$5.34M$5.27M$4.47M$4.19M$4.43M$3.71M$3.39M$29.57M$17.87M$16.73M$14.52M$4.13M
Low Forecast$2.23M$2.11M$2.01M$3.38M$5.21M$948.12K$1.09M$5.82M$2.52M$4.75M$1.14M$1.05M$1.20M$4.83M$4.86M$4.82M$5.40M$5.34M$5.27M$4.47M$4.19M$4.43M$3.71M$3.39M$29.57M$17.87M$16.73M$14.52M$2.75M
Surprise %--------0.23%1.49%1.45%1.67%1.19%1.20%1.25%1.26%1.28%1.12%1.11%1.08%1.17%0.87%1.50%1.83%0.22%0.35%0.91%1.24%5.08%

Aclaris Therapeutics's average Quarter SG&A projection for Mar 24 is $5.82M, based on 4 Wall Street analysts, with a range of $5.82M to $5.82M. The forecast indicates a 76.53% rise compared to ACRS last annual SG&A of $3.30M (Dec 23).

Aclaris Therapeutics EPS Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19Mar 19Mar 18
# Analysts11136334756322223456464474379
EPS---------$-0.00$-0.00$-0.39$-0.50$-0.32$-0.25$-0.28$-0.37$-0.35$-0.34$-0.57$-0.30$-0.25$-0.28$-0.37$-0.45$-1.34$-1.21$-0.91$-0.98
Avg Forecast$-0.15$-0.15$-0.13$-0.13$-0.14$-0.01$-0.20$-0.29$-0.34$-0.48$-0.45$-0.44$-0.45$-0.39$-0.36$-0.39$-0.36$-0.28$-0.28$-0.30$-0.31$-0.31$-0.35$-0.38$-0.04$-0.69$-0.76$-0.80$-1.02
High Forecast$0.01$0.01$0.01$-0.08$-0.12-$0.01$0.01$-0.17$0.02$0.02$0.02$0.02$-0.39$-0.36$-0.39$-0.36$-0.28$-0.28$-0.30$-0.31$-0.31$-0.35$-0.38$-0.04$-0.69$-0.76$-0.80$-0.82
Low Forecast$-0.64$-0.61$-0.54$-0.17$-0.17$-0.02$-0.86$-1.19$-0.40$-2.00$-1.88$-1.83$-1.86$-0.39$-0.36$-0.39$-0.36$-0.28$-0.28$-0.30$-0.31$-0.31$-0.35$-0.38$-0.04$-0.69$-0.76$-0.80$-1.22
Surprise %---------0.00%0.00%0.89%1.12%0.82%0.70%0.71%1.01%1.24%1.24%1.87%0.98%0.80%0.79%0.99%12.86%1.94%1.60%1.13%0.96%

According to undefined Wall Street analysts, Aclaris Therapeutics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to ACRS previous annual EPS of $NaN (undefined).

Aclaris Therapeutics Peer Comparison by Price Target

TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
ACRSAclaris Therapeutics$3.14$14.00345.86%Buy
GTHGenetron$4.03$10.00148.14%-
BDSXBiodesix$1.26$3.00138.10%Buy
MYGNMyriad Genetics$15.22$29.0090.54%Hold
ICLRICON Public Limited Company$187.22$309.6065.37%Buy
CSTLCastle Biosciences$27.90$40.5045.16%Buy
IQVIQVIA$191.04$266.6539.58%Buy
MEDPMedpace$308.93$399.2029.22%Hold
QGENQiagen$40.99$51.8926.59%Buy
SHCSotera Health Company$13.88$17.4325.58%Buy
NEOGNeogen$15.20$17.5015.13%Buy
RDNTRadNet$79.09$69.00-12.76%Buy
OLKOlink AB (publ)$26.08$21.50-17.56%Hold

ACRS Forecast FAQ

Is Aclaris Therapeutics a good buy?

Yes, according to 5 Wall Street analysts, Aclaris Therapeutics (ACRS) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 2 'Buy' recommendations, accounting for 40.00% of ACRS's total ratings.

What is ACRS's price target?

Aclaris Therapeutics (ACRS) average price target is $14 with a range of $3 to $25, implying a 345.86% from its last price of $3.14. The data is based on 5 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Aclaris Therapeutics stock go up soon?

According to Wall Street analysts' prediction for ACRS stock, the company can go up by 345.86% (from the last price of $3.14 to the average price target of $14), up by 696.18% based on the highest stock price target, and down by -4.46% based on the lowest stock price target.

Can Aclaris Therapeutics stock reach $5?

ACRS's average twelve months analyst stock price target of $14 supports the claim that Aclaris Therapeutics can reach $5 in the near future.

What is Aclaris Therapeutics's current price target trend?

1 Wall Street analyst forecast a $3 price target for Aclaris Therapeutics (ACRS) this month, down -4.46% from its last price of $3.14. Compared to the last 3 and 12 months, the average price target decreased by -4.46% and decreased by -4.46%, respectively.

What are Aclaris Therapeutics's analysts' financial forecasts?

Aclaris Therapeutics's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $11.17M (high $25.3M, low $4.33M), average EBITDA is $-36.78M (high $-24.438M, low $-56.424M), average net income is $-52.659M (high $-30.061M, low $-108M), average SG&A $33.69M (high $76.33M, low $13.07M), and average EPS is $-0.633 (high $-0.0974, low $-2.239). ACRS's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $13.78M (high $41.65M, low $3.22M), average EBITDA is $-13.785M (high $-3.225M, low $-41.654M), average net income is $-39.795M (high $-4.442M, low $-140M), average SG&A $41.59M (high $125.66M, low $9.73M), and average EPS is $-0.557 (high $-0.0622, low $-1.964).

Did the ACRS's actual financial results beat the analysts' financial forecasts?

Based on Aclaris Therapeutics's last annual report (Dec 2023), the company's revenue was $31.25M, beating the average analysts forecast of $9.88M by 216.36%. Apple's EBITDA was $-97.357M, beating the average prediction of $-33.167M by 193.53%. The company's net income was $-88.481M, missing the average estimation of $-116M by -23.91%. Apple's SG&A was $32.41M, beating the average forecast of $29.8M by 8.77%. Lastly, the company's EPS was $-0.0013, missing the average prediction of $-1.711 by -99.92%. In terms of the last quarterly report (Dec 2023), Aclaris Therapeutics's revenue was $17.57M, beating the average analysts' forecast of $4.66M by 277.34%. The company's EBITDA was $-4.047M, missing the average prediction of $-4.656M by -13.08%. Aclaris Therapeutics's net income was $-1.491M, missing the average estimation of $-24.587M by -93.94%. The company's SG&A was $3.3M, missing the average forecast of $14.05M by -76.54%. Lastly, the company's EPS was $0, missing the average prediction of $-0.344 by -100.00%